Company / Accounts Receivable
Progyny Accounts Receivable History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$220.3M
FY2025
5-year range
$134.6M / $241.9M
FY2021-FY2025
Trend
-6.4%
vs FY2024
Sector context
#69 of 143
Health Care
What the data says
At $220M, Progyny's accounts receivable ranks #69 of 143 in the Health Care sector. Declined from $242M to $220M over the past 2 years.
Based on SEC 10-K filings.
$220M in FY2025 with a 5-year CAGR of +23.8%.
Declined from $242M to $220M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -2.8%
- 5-Year CAGR
- +23.8%
- 10-Year CAGR
- -
Sector benchmark
#69 of 143 in Health CareTop 48% of 143This company $220.3M Sector average $1.3B
▼
-83.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +23.8%, indicating consistent growth.
- In FY2025, accounts receivable decreased 6.4% year-over-year.
- Ranks #69 out of 143 companies in the Health Care sector.
- Peak accounts receivable was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 3.62 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $220.3M | -6.4% |
| FY2024 | $235.3M | -2.7% |
| FY2023 | $241.9M | +0.8% |
| FY2022 | $240.1M | +78.4% |
| FY2021 | $134.6M | +77.8% |
| FY2020 | $75.7M | +60.8% |
| FY2019 | $47.1M | +101.8% |
| FY2018 | $23.3M | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026